Abstract: TH-PO0468
Effectiveness of Magnetic Field Therapy in Reducing Arteriovenous Fistula Puncture Pain in Patients on Hemodialysis
Session Information
- Hemodialysis: Novel Markers and Case Reports
November 06, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Dialysis
- 801 Dialysis: Hemodialysis and Frequent Dialysis
Authors
- Tsuchiya, Yukiko, The Jikei University School of Medicine, Tokyo, Japan
- Uchiyama, Taketo, The Jikei University School of Medicine, Tokyo, Japan
- Kato, Kazuhiko, The Jikei University School of Medicine, Tokyo, Japan
- Nakashima, Akio, The Jikei University School of Medicine, Tokyo, Japan
- Tokudome, Gorou, The Jikei University School of Medicine, Tokyo, Japan
- Yokoo, Takashi, The Jikei University School of Medicine, Tokyo, Japan
Background
Arteriovenous fistula puncture pain significantly affects the quality of life of patients undergoing hemodialysis. Several interventions have been investigated to alleviate this pain, including lidocaine/prilocaine cream and lidocaine tape. However, none have proven effective in eliminating pain. Alternating magnetic fields have been reported to exert analgesic effects in rodents and humans by stimulating the descending pain suppression system. AT-04, a portable magnetic field-generating device, was designed to alleviate pain using magnetic stimulation, which is beneficial for managing pain under different conditions. This study aimed to investigate the effectiveness of AT-04 in alleviating arteriovenous fistula puncture pain in patients undergoing hemodialysis.
Methods
This study included patients who received hemodialysis between July and August 2024. AT-04 was applied before the arteriovenous fistula puncture. The pain intensity of the puncture was assessed using the Visual Analog Scale (VAS) before the application of AT-04 and at 1 and 4 weeks after its application. The main endpoint was the change in the VAS score for arteriovenous fistula puncture pain after the application of AT-04.
Results
A total of 14 patients with an average age of 80 years (IQR, 74–85) were included in this study. The mean dialysis duration was 5.8 years (IQR,1.0–8.9). The median VAS score was 40.5 (IQR, 23.5–55.5) before using AT-04. The median VAS score decreased to 27.0 (IQR, 4.5–32.8) 1 week after using AT-04 and further decreased to 16.5 (IQR, 5.0–38.8) 4 weeks later. These decreases were statistically significant compared with the pretreatment VAS score (1 week, P = 0.0057; 4 weeks, P = 0.0076). No significant complications were associated with the application of AT-04.
Conclusion
AT-04 provided considerable arteriovenous fistula puncture pain relief in patients undergoing hemodialysis. AT-04 is a novel approach to reducing arteriovenous fistula puncture pain in patients undergoing hemodialysis.
Funding
- Private Foundation Support